Clover Biopharmaceuticals, Ltd. (HKG:2197)

Market Cap	271.09M
Revenue (ttm)	40.88M
Net Income (ttm)	-961.40M
Shares Out	1.30B
EPS (ttm)	-0.77
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	462,500
Average Volume	1,250,904
Open	0.2000
Previous Close	0.2060
Day's Range	0.2000 - 0.2190
52-Week Range	0.1850 - 0.5800
Beta	3.60
RSI	39.12
Earnings Date	May 27, 2025

About Clover Biopharmaceuticals

Clover Biopharmaceuticals, Ltd., a biotechnology company, engages in the research and development, manufacture, and commercialization of vaccines in Mainland China. Its product candidates include SCB-2019 (CpG 1018/Alum), a COVID-19 vaccine; AdimFlu-S (QIS), a quadrivalent split inactivated vaccine for the treatment of influenza A and B; SCB-219M, a thrombopoietin receptor agonist mimetic bispecific Fc-fusion protein to treat cancer patients with chemotherapy-induced thrombocytopenia; and SCB-313, an oncology product candidate for the treatment...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2007
• Employees: 387
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 2197

Financial Performance

In 2024, Clover Biopharmaceuticals's revenue was 38.42 million, a decrease of -2.13% compared to the previous year's 39.26 million. Losses were -903.43 million, 552.1% more than in 2023.

Financial numbers in CNY